CHF Solutions has raised $5.39m through a public offering of 2.5 million shares of its common stock.
CHF will grant the underwriters an over-allotment option to purchase 0.33 million additional shares of its common stock priced at $2.12 a share.
Based in the US, CHF Solutions is a medical device company that develops fluid management solutions.
The company plans to use the funds towards general corporate purposes and to expand its business.
Honigman Miller Schwartz and Cohn LLP was appointed as legal adviser to CHF Solutions for the offering.
Myomo plans to raise $75m through a public offering of securities.
The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.
Based in the US, Myomo is a medical device company that develops myoelectric braces for neuromuscular disorders.
The company plans to use the funds raised from the offering towards working capital, clinical development, product acquisitions, and other general corporate purposes.
Goodwin Procter has been appointed as the legal adviser to Myomo for the offering.
UK-based diagnostics company Quotient has raised $36m through a second tranche of senior notes due 2023.
The proceeds from the offering are intended to be used for general corporate purposes.
MedCrypt has raised $1.9m through a seed financing round provided by Eniac Ventures.
The round also included the participation of Sway Ventures, Nex Cubed, Oronoco Investments and Friedman BioVentures.
The current transaction brings the total funds raised by the company to $1.52m.
MedCrypt plans to use the funds towards the development of cryptographically embedded cybersecurity software for medical device producers and its customers, Reflexion Medical and QuiO.
Based in the US, MedCrypt is a cybersecurity services provider for medical devices.
Compumedics has signed a three-year distribution agreement worth A$3.6m ($2.7m) with Fukuda Denshi (Fu kuda) for the supply of the former’s complete range of neuro-diagnostic and monitoring systems in the Japanese market.
Based in Australia, Compumedics is a neuro-diagnostics solutions provider, while Fukuda is a Japanese medical device company that manufactures cardiovascular and respiratory systems.
The agreement will enable Compumedics to expand its footprint in Japan.